Light the world teal for November’s Alzheimer’s Awareness Month
Oct 31, 2024 · To help advocates get the word out, the AFA has prepared resources including an Alzheimer’s fact sheet and tips for healthy aging.The foundation also is offering images that can be used as cover photos to tell the world about going teal for Alzheimer’s awareness and loving someone with Alzheimer’s.. Alzheimer’s disease is a neurological condition marked by problems with memory and ...
Muna, GSK partner to develop targets for Alzheimer's treatments
Dec 6, 2024 · The research collaboration will leverage Muna’s MiND-MAP platform, which analyzes analyze post-mortem brain samples from people with Alzheimer’s and compares them with the brains of healthy individuals, centenarians with and without cognitive impairment, and people without cognitive decline despite age or exposure to risk factors.. This approach is designed to help uncover the genetic and ...
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
Jul 11, 2024 · Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain. Patients also reported less fatigue, a common symptom of MS. “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a ...
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
Sep 26, 2024 · The board’s findings were announced by therapy developer Cassava Sciences, which said in a press release that the company expects to share data from one clinical trial later this year, and from the other by the middle of next year.. The two trials, dubbed RETHINK-ALZ (NCT04994483) and REFOCUS-ALZ (NCT05026177), have collectively enrolled 1,929 people with mild to moderate Alzheimer’s.
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
Sep 22, 2023 · These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon’s experimental therapy preserved the hippocampus, a brain structure important for memory that is damaged first in Alzheimer’s.. Importantly, ALZ-801’s safety profile over two years continued to show no increased risk of brain swelling and bleeds, which have ...
Neurostimulation Device for Alzheimers Granted FDA …
Jan 25, 2021 · The device uses gamma frequency technology — called GENUS, for gamma entrainment using sensory stimuli — as a way to stimulate the brain in a non-invasive way.This can be done as an auditory (via sound) or visual (via light) stimulation. In mouse models of Alzheimer’s disease, researchers had already observed that, prior to the onset of cognitive decline, the brain showed a pattern of ...
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
Blarcamesine sustains benefits in early Alzheimer’s over year: Data
Aug 1, 2024 · In Alzheimer’s, misfolded proteins build up into toxic clumps that disrupt the normal functioning of nerve cells, leading to brain damage. This slowly impairs memory and thinking skills, and eventually the ability to carry out the simplest tasks in daily life. “People living with early Alzheimer’s disease have the desire to maintain their sense of self for as long as possible,” said ...
Modified Kisunla dosing lowers risk of ARIA-E in Alzheimer’s: Study
Nov 8, 2024 · The modified dosing regimen reduced ARIA-E the most in patients with two copies of the ApoE4 gene variant, which is known to have a high genetic risk for Alzheimer’s. With the modification, 19% of these patients experienced ARIA-E compared with 57% on the standard dosing regimen, lowering their relative risk by 67%, according to Eli Lilly.
Alzamend Neuro sets trial dosage for AL001 lithium therapy
Oct 24, 2024 · Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials.